BackImago BioSciences Overview

Imago BioSciences Intangible Assets

Imago BioSciences's intangible assets is $0.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$0.00

Peer trimmed avg / median

Loading

Imago BioSciences Intangible Assets History

Loading

Imago BioSciences vs. peers: Intangible Assets Comparison

Loading

Imago BioSciences Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Imago BioSciences (IMGO) FAQ

As of the most recent data (September 2022), IMGO shows a intangible assets of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IMGO's intangible assets is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Imago BioSciences is outperforming or lagging.

Tracking IMGO's intangible assets over time shows whether Imago BioSciences is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this intangible assets page, Stockcircle has Imago BioSciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect intangible assets (currently $0) with ownership activity and broader fundamentals.

Imago BioSciences's intangible assets is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.